Raxar Side Effects Center

Last updated on RxList: 10/18/2022
Raxar Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Raxar?

Raxar (grepafloxacin) is an antibiotic used to treat various types of bacterial infections. The brand name Raxar is discontinued, but generic versions may be available.

What Are Side Effects of Raxar?

Common side effects of Raxar (grepafloxacin) include:

Raxar may cause serious side effects including:

  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • dizziness,
  • irregular heart rate,
  • burning or stinging sensation in your skin,
  • rash, 
  • liver enzyme abnormalities,
  • joint pain, and
  • stiffness and swelling in your joints, and
  • clicking or grinding sensation in your joints

Get medical help right away, if you have any of the symptoms listed above.

Seek medical care or call 911 at once if you have the following serious side effects:

  • Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
  • Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in your chest; shortness of breath; and sudden dizziness, lightheadedness, or passing out;
  • Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors.

This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.

Dosage for Raxar

The usual dose for Raxar is 400 mg or 600 mg orally every 24 hours.

What Drugs, Substances, or Supplements Interact with Raxar?

Raxar may interact with antacids containing magnesium or aluminum, vitamin or mineral supplements containing iron or zinc, heart medicines, terfenadine, astemizole, antidepressants, phenothiazines, erythromycin, cisapride, warfarin, theophylline, insulin or an oral diabetes medication, or nonsteroidal anti-inflammatory drugs (NSAIDs). Tell your doctor all medications and supplements you use.

Raxar During Pregnancy or Breastfeeding

It is unknown if Raxar will harm a fetus. Do not take this medication without first talking to your doctor if you are pregnant. This drug passes into breast milk and may harm a nursing infant. It may affect bone development. Consult your doctor before breastfeeding.

Additional Information

Our Raxar (grepafloxacin) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

QUESTION

About how much does an adult human brain weigh? See Answer
Raxar Professional Information

SIDE EFFECTS

Adverse reactions were assessed in clinical trials involving approximately 2500 patients receiving single-dose or multiple-dose regimens of grepafloxacin.

Multiple dose Regimens

Most of the adverse reactions reported in clinical trials were transient in nature, mild to moderate in severity, and required no treatment. Twenty of 1069 patients (1.9%) receiving grepafloxacin 400 mg daily and 50 of 925 patients (5.4%) receiving grepafloxacin 600 mg daily discontinued RAXAR (grepafloxacin) Tablets due to an adverse reaction thought by the investigator to be drug-related.

Table 3 lists adverse events that occurred with frequencies of 1% or greater. These events were thought by the investigators to be drug-related in patients treated with grepafloxacin in multiple dose clinical trials.

Table 3
Drug-related Adverse Reactions in Grepafloxacin Treated Patients on Multiple dose Dosing Regimens in Clinical Trials

Adverse Reaction
400 mg daily (n=1069)
600 mg daily (n=925)
Nausea
11.1 %
15.8 %
Taste perversion
9.0 %
17.8 %
Headache
4.6 %
4.9 %
Dizziness
4.3 %
5.4 %
Diarrhea
3.5 %
4.2 %
Vaginitis
3.3 %
1.4 %
Abdominal pain
2.2 %
2.1 %
Vomiting
1.7 %
5.7 %
Pruritus
1.6 %
1.2 %
Dyspepsia
1.5 %
3.1 %
Leukorrhea
1.4 %
0.0 %
Asthenia
1.4 %
2.3 %
Infection
1.3 %
0.4 %
Insomnia
1.3 %
2.1 %
Rash
1.1 %
1.9 %
Anorexia
0.8 %
1.8 %
Somnolence
1.0 %
1.5 %
Dry mouth
0.8 %
1.1 %
Photosensitivity reaction
0.7 %
1.8 %
Constipation
0.7 %
2.2 %
Pain
0.6 %
1.0 %
Nervousness
0.6 %
1.7 %

Additional drug-related events, occurring in multiple-dose clinical trials at a rate of less than 1% were:

Body as a Whole: Back pain, body odor, chest pain, chills, facial edema, fever, malaise, neck rigidity, pelvic pain.

Cardiovascular System: Arrhythmia, hypotension, palpitations, peripheral vascular disorder, postural hypotension, syncope, tachycardia, vasodilatation.

Digestive System: Abnormal liver function tests, abnormal stools, cheilitis, dysphagia, eructation, flatulence, gastritis, gastrointestinal disorder, gingivitis, glossitis, increased appetite, melena, mouth ulceration, oral moniliasis, rectal disorder, rectal hemorrhage, stomatitis, tenesmus, thirst, tongue discoloration, tongue disorder, tongue edema.

Hemic and Lymphatic System: Anemia, eosinophilia, hypochromic, anemia, leukocytosis, leukopenia, lymphadenopathy, lymphocytosis, lymphoma like reaction, prothrombin decreased, prothrombin increased, reticuloendothelial hyperplasia, thrombocytopenia, thromboplastin increased.

Metabolic and Nutritional System: Dehydration, edema, electrolyte abnormality, gout, hyperglycemia, hyperlipidemia, hypernatremia, hyperuricemia, increased alkaline phosphatase, increased BUN, increased creatinine, increased gamma glutamyl transpeptidase, increased SGOT, increased SGPT, peripheral edema, weight loss.

Musculoskeletal System: Arthralgia, myalgia.

Nervous System: Abnormal dreams, abnormal gait, agitation, anxiety, confusion, depression, emotional lability, hallucinations, hyperkinesia, hypesthesia, hypokinesia, paresthesia, speech disorder, stupor, thinking abnormal, tremor, vertigo.

Respiratory System: Asthma, atelectasis, bronchitis, dyspnea, epistaxis, hemoptysis, increased cough, laryngismus, pharyngitis, pleural effusion, rhinitis, sputum increased.

Skin and Appendages: Acne, alopecia, dry skin, epidermal necrolysis, exfoliative dermatitis, fungal dermatitis, herpes simplex, maculopapular rash, skin disorder, sweating, urticaria, vesiculobullous rash.

Special Senses: Amblyopia, conjunctivitis, deafness, dry eyes, ear disorder, eye pain, lacrimation disorder, parosmia, photophobia, taste loss, tinnitus.

Urogenital System: Albuminuria, balanitis, dysuria, hematuria, impotence, polyuria, urethral pain, uricaciduria, urinary frequency, urinary tract disorder, urination impaired, urine abnormality, vulvovaginal disorder.

Single dose Regimens

In clinical trials, patients were treated for uncomplicated gonorrhea using a single dose of RAXAR (grepafloxacin) 400 mg. There were no deaths or permanent disabilities in these studies.

Table 4 lists the adverse events which occurred with frequencies of 1% or greater. These events were thought by the investigators to be drug related in patients treated with RAXAR (grepafloxacin) Tablets in single-dose clinical trials.

Table 4
Drug-related Adverse Reactions in Grepafloxacin Treated Patients on a Single dose Dosing Regimen in Clinical Trials

Adverse Reaction
400 mg daily (n=487)
Vaginitis
5.0%
Nausea
3.3%
Dizziness
2.1%
Vomiting
2.1%
Headache
1.8%
Leukorrhea
1.2%
Abdominal pain
1.2%
Diarrhea
1.2%
Pruritus
1.2%
Taste perversion
1.2%

Additional drug-related events occurring in single dose clinical trials at a rate of less than 1 were:

    Body as a Whole: Asthenia, chest pain, chills, flu-like syndrome, infection, malaise.
    Cardiovascular System: Syncope, vasodilatation.
    Digestive System: Anorexia, constipation, increased appetite, tenesmus.
    Hemic and Lymphatic System: Lymphadenopathy.
    Nervous System: Hyperkinesia, insomnia, nervousness, somnolence.
    Respiratory System: Rhinitis.
    Skin and Appendages: Acne, rash, sweating.
    Urogenital System: Balanitis.

Observed During Clinical Practice

In addition to adverse reactions reported from clinical trials the following events have been identified during post-approval use of grepafloxacin formulations. Because they are reported voluntarily from a population of unknown size estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to grepafloxacin.

    Eye: Disturbances in vision.
    Non Site specific: Allergic reactions, including anaphylactoid reaction/anaphylactic shock, angioedema, laryngeal edema.

Read the entire FDA prescribing information for Raxar (Grepafloxacin)

SLIDESHOW

Digestive Disorders: Common Misconceptions See Slideshow

© Raxar Patient Information is supplied by Cerner Multum, Inc. and Raxar Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors